La Jolla Pharmaceutical Company

Informe acción NasdaqCM:LJPC

Capitalización de mercado: US$155.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La Jolla Pharmaceutical Dirección

Dirección controles de criterios 3/4

El CEO de La Jolla Pharmaceutical es Larry Edwards , nombrado en Jul 2020, tiene una permanencia de 2.08 años. compensación anual total es $2.39M, compuesta por 23% salario y 77% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.048% de las acciones de la empresa, por valor de $74.45K. La antigüedad media del equipo directivo y de la junta directiva es de 2.1 años y 7.7 años, respectivamente.

Información clave

Larry Edwards

Chief Executive Officer (CEO)

US$2.4m

Compensación total

Porcentaje del salario del CEO23.0%
Permanencia del CEO2.1yrs
Participación del CEO0.05%
Permanencia media de la dirección2.1yrs
Promedio de permanencia en la Junta Directiva7.7yrs

Actualizaciones recientes de la dirección

Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

Jan 05
Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

Recent updates

Innoviva to acquire La Jolla Pharma for $149M including debt

Jul 11

We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are Conservative

Nov 11
We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are Conservative

Our Take On La Jolla Pharmaceutical Company

Jul 02

La Jolla Pharmaceutical EPS misses by $0.14, beats on revenue

May 07

La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their Shares

Mar 11
La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their Shares

Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Feb 11
Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%

Jan 16
Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%

La Jolla Pharmaceutical rallies on exclusive licensing agreement with PAION

Jan 12

Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

Jan 05
Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?

Dec 09
Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?

La Jolla Pharmaceutical EPS beats by $0.11, beats on revenue

Nov 09

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Larry Edwards en comparación con los beneficios de La Jolla Pharmaceutical?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2022n/an/a

US$4m

Mar 31 2022n/an/a

US$5m

Dec 31 2021US$2mUS$550k

US$20m

Sep 30 2021n/an/a

US$12m

Jun 30 2021n/an/a

US$3m

Mar 31 2021n/an/a

-US$16m

Dec 31 2020US$3mUS$208k

-US$39m

Compensación vs. Mercado: La compensación total de Larry($USD2.39M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.44M).

Compensación vs. Ingresos: La compensación de Larry ha sido consistente con los resultados de la empresa en el último año.


CEO

Larry Edwards (50 yo)

2.1yrs

Permanencia

US$2,389,409

Compensación

Mr. Larry G. Edwards has been President and Chief Executive Officer at La Jolla Pharmaceutical Company since July 2020. Mr. Edwards serves as Director at La Jolla Pharmaceutical Company since October 29, 2...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Larry Edwards
President2.1yrsUS$2.39m0.048%
$ 74.5k
Michael Hearne
CFO & Secretary2.2yrsUS$504.10k0.041%
$ 63.4k
Paula Rusu
Vice President of Operations1.8yrssin datossin datos
Sandra Vedrick
Senior Director of Investor Relations & Human Resourcesno datasin datossin datos
Luke Seikkula
Senior Vice President of Pharmaceutical Operations3.5yrssin datossin datos
Lakhmir Chawla
Consultant7.1yrsUS$707.29ksin datos
Stewart Kroll
Chief Development Officer2.7yrssin datossin datos
Mark Williams
Senior Vice President of Medical Affairs1.9yrssin datossin datos
Tony Hodges
Chief Medical Officerless than a yearsin datossin datos

2.1yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LJPC se considera experimentado (2.1 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Larry Edwards
President1.8yrsUS$2.39m0.048%
$ 74.5k
Kevin Tang
Chairman of the Board8yrsUS$105.86k0.45%
$ 696.6k
David Ramsay
Independent Director2.8yrsUS$165.86k0.40%
$ 622.0k
Tomas Ganz
Member of Scientific Advisory Board8.5yrssin datossin datos
Laura Douglass
Independent Director8.8yrsUS$165.86k0.0020%
$ 3.1k
Elizabeta Nemeth
Member of Scientific Advisory Board8.5yrssin datossin datos
Craig Johnson
Independent Director8.8yrsUS$180.86k0.048%
$ 74.6k
Robert Rosen
Independent Director8.1yrsUS$165.86k0%
$ 0
Paul Adams
Member of Advisory Board7.3yrssin datossin datos
Victor Gordeuk
Member of Advisory Board7.3yrssin datossin datos
Ashutosh Lal
Member of Advisory Board7.3yrssin datossin datos
Gordon McLaren
Member of Advisory Board7.3yrssin datossin datos

7.7yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de LJPC se considera experimentada (7.7 años de antigüedad promedio).